Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Integrated Pharmaceuticals, Inc. (OTC: INTP).

Full DD Report for INTP

You must become a subscriber to view this report.


Recent News from (OTC: INTP)

Intec Pharma Reports Third Quarter 2017 Operating and Financial Results
JERUSALEM , Nov. 15, 2017 /PRNewswire/ -- Intec Pharma LTD (NASDAQ: NTEC) (TASE: NTEC) today announced its third quarter 2017 financial results and provided a corporate update. "The third quarter was truly transformational for Intec Pharma.  We advanced our clinical development pr...
Source: PR Newswire
Date: November, 15 2017 16:01
Intec Pharma Announces Pricing of $50.0 Million Public Offering of Ordinary Shares
JERUSALEM , August 16, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the pricing of an underwritten public offering of approximately 10.6 million of its ordinary shares at a public offering price of $4.70 per ordinary share. The gross proceeds of the o...
Source: PR Newswire
Date: August, 16 2017 09:00
Intec Pharma Granted Patent in Hong Kong for Accordion Pill(TM) Carbidopa / Levodopa
JERUSALEM , July 19, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ, TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that the Patent Registry Intellectual Property Department...
Source: PR Newswire
Date: July, 19 2017 08:00
Intec Pharma Appoints U.S. Life Sciences Executive and Vice Chairman Jeffrey A. Meckler as Chief Executive Officer
JERUSALEM , July 10, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces the appointment of Jeffrey A. Meckler as Chief ...
Source: PR Newswire
Date: July, 10 2017 08:33
Intec Pharma Granted U.S. Patent for Accordion Pill(TM) Comprising Levodopa for Improved Treatment of Parkinson's Diseases Symptoms
JERUSALEM , May 24, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that the United States Patent and Trademark Office has granted...
Source: PR Newswire
Date: May, 24 2017 08:30
Intec Pharma Appoints U.S. Life Sciences Executive Jeffrey A. Meckler to its Board of Directors as Vice Chairman
JERUSALEM , April 9, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced the appointment of Jeffrey A. Meckler as Vice Chairm...
Source: PR Newswire
Date: April, 09 2017 02:15
Intec Pharma Reports 2016 Fourth Quarter and Full Year Financial Results
JERUSALEM , April 7, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq and TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today reported financial results for the three and 12 month...
Source: PR Newswire
Date: April, 07 2017 08:00
Intec Pharma Initiates Phase I Trial of Accordion Pill for Cannabinoid Therapies
JERUSALEM , March 22, 2017 /PRNewswire/ -- Expects Phase I Results in the Third Quarter of 2017 Intec Pharma Ltd. (Nasdaq; TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces...
Source: PR Newswire
Date: March, 22 2017 07:00
Intec Pharma to Participate in the Oppenheimer 27th Annual Healthcare Conference
JERUSALEM , March 17, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC), a late stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that the Company will participate at the Oppenheimer 27th A...
Source: PR Newswire
Date: March, 17 2017 16:00
Intec Pharma Announces $10 Million Private Placement
JERUSALEM , March 10, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ; TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it has entered into agreements with several investo...
Source: PR Newswire
Date: March, 10 2017 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-17N/A0.0016N/AN/A0
2018-08-16N/A0.0016N/AN/A0
2018-08-15N/A0.0016N/AN/A0
2018-08-14N/A0.0016N/AN/A0
2018-08-13N/A0.0016N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-07-25125,000250,00050.0000Short
2018-07-2470,000133,00052.6316Short
2018-07-183,00013,00023.0769Cover
2018-07-1780,000140,00057.1429Short
2018-07-16470,2001,287,50036.5204Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on INTP.


About Integrated Pharmaceuticals, Inc. (OTC: INTP)

Logo for Integrated Pharmaceuticals, Inc. (OTC: INTP)

Not available

 

 

 

Current Management

  • Brad Nightingale / President
  • Luke Zouvas / Securities Counsel

Current Share Structure

  • Market Cap: $94,172 - 03/09/2018
  • Authorized: 75,000,000 - 11/15/2004
  • Issue and Outstanding: 47,085,758 - 04/20/2011

 



Daily Technical Chart for (OTC: INTP)

Daily Technical Chart for (OTC: INTP)


Stay tuned for daily updates and more on (OTC: INTP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: INTP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in INTP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of INTP and does not buy, sell, or trade any shares of INTP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/